Payment overview · 2025
General Payments
$423.13
21 reported records · 10 companies
Healthcare provider profile · identity verified
Julie Henson
Allopathic & Osteopathic Physicians|Family Medicine · BOLIVAR, MO · NPI 1477912731
Verified facts
What the public records show
CMS Open Payments records show Julie Henson received $423.13 in general payments during 2025 across 21 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $119.72 | 28.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.30 | 17.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.47 | 11.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.88 | 9.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.54 | 9.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.28 | 6.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.54 | 5.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.20 | 4.3% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $16.88 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.32 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $423.13 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $119.72 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $51.28 | 3 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $40.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 336 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 270 | 104 |
| Lisinopril | Lisinopril | 250 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 76 |
| Gabapentin | Gabapentin | 211 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 211 | 73 |
| Omeprazole | Omeprazole | 204 | 71 |
| Tramadol Hcl | Tramadol Hcl | 178 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 60 |
| Celecoxib | Celecoxib | 152 | 49 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 143 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 47 |
| Pregabalin | Pregabalin | 125 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 40 |
| Potassium Chloride | Potassium Chloride | 106 | 32 |
| Furosemide | Furosemide | 105 | 29 |
| Losartan Potassium | Losartan Potassium | 104 | 38 |
| Metformin Hcl | Metformin Hcl | 103 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 92 | 20 |
| Alprazolam | Alprazolam | 88 | 23 |
| Simvastatin | Simvastatin | 88 | 26 |
| Methocarbamol | Methocarbamol | 84 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 29 |
| Metformin Hcl Er | Metformin Hcl | 79 | 18 |
| Trazodone Hcl | Trazodone Hcl | 76 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 24 |
| Jardiance | Empagliflozin | 71 | 21 |
| Sertraline Hcl | Sertraline Hcl | 70 | 30 |
| Bupropion Xl | Bupropion Hcl | 68 | 25 |
| Alendronate Sodium | Alendronate Sodium | 67 | 14 |
| Mirtazapine | Mirtazapine | 66 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 12 |
| Meloxicam | Meloxicam | 63 | 22 |
| Montelukast Sodium | Montelukast Sodium | 63 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 20 |
| Buspirone Hcl | Buspirone Hcl | 60 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 22 |
| Eliquis | Apixaban | 54 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 18 |
| Clonazepam | Clonazepam | 47 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 11 |
| Allopurinol | Allopurinol | 44 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 18 |
| Baclofen | Baclofen | 42 | 15 |
| Prednisone | Prednisone | 42 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 32 |
| Mupirocin | Mupirocin | 41 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Doxepin Hcl | Doxepin Hcl | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Famotidine | Famotidine | 37 | 17 |
| Ondansetron Odt | Ondansetron | 37 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 11 |
| Glimepiride | Glimepiride | 35 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 19 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 11 |
| Lovastatin | Lovastatin | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 21 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Wegovy | Semaglutide | 20 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Acyclovir | Acyclovir | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $423.13 · 21 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, ABILIFY MAINTENA, AUSTEDO XR, CAPLYTA, CHARTIS CATHETER, Dexcom G6 Transmitter, KISUNLA, MOUNJARO, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REXULTI, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, Wegovy, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error